International Isotopes CEO Bagerdjian signs 5-year employment agreement; Dr. Fu appointed to board

RADNOSTIX INC

CEO Shahe Bagerdjian's base salary set at $314K with automatic 5% annual increases through 2030 and up to $250K in milestone raises based on quarterly revenue hitting $3.75M–$25M.
Bagerdjian awarded 37.5M RSUs vesting in tranches at share prices of $0.10 to $0.30 over 60 consecutive calendar days; immediate vesting upon termination without cause or change of control.
Dr. Duke W. Fu, nuclear pharmacist executive, appointed to board and audit committee; receives 250K RSUs annually.
Bylaws amended: clarify special meeting business, add advance notice for shareholder proposals and director nominations, allow advisory directors, and update indemnification/insurance provisions.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

RADNOSTIX INC: Amended bylaws to revise special meeting procedures, add advance notice requirements for business and director nominations, add advisory director provisions, revise written consent by shareholders, and add sections on indemnification and insurance (effective 2025-10-14).

Change: bylaw amendment
Effective: 2025-10-14

Exact text from the filing

On October 14, 2025, the Board approved changes to the Company’s bylaws (the “Bylaws”), which are summarized below, and which are attached in full as an exhibit hereto.

View on SEC.gov

270 governance changes filed in the last 30 days. Browse all governance changes →

RADNOSTIX INC filing history →

Source: SEC EDGAR

accession 0001437749-25-031241

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.